- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01305057
Efficacy Test on Skin Hydration and Skin Barrier Function
February 25, 2011 updated by: Cosmos Technical Center
Human Use Test on Skin Hydration and Skin Barrier Function
The effects of topically applied pyridoxine tri-isopalmitate (P-IP) which stimulates filaggrin synthesis in keratinocytes, on skin hydration and barrier function were examined.
Subjects were separated into two groups to examine the effect of P-IP.
Subjects were treated with P-IP formulation on one side of the face and with a placebo formulation on the other side twice daily (morning and evening) for 28 days.
All subjects gave written informed consent prior to the study.
The skin hydration and TEWL (transepidermal water loss) were evaluated by measuring skin surface conductance with a skin hygrometer SKICON 200EX (I.B.S. ltd., Japan) and TEWL meter AS-CT1 (ASAHI BIOMED, Tokyo, Japan), respectively.
Study Overview
Detailed Description
It is expected that the long-term application of P-IP increase skin surface water contents and suppress TEWL.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Itabashi-ku, Tokyo, Japan, 174-0046
- Cosmos Technical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
31 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy skin
Exclusion Criteria:
- don't use any moisturizer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Evaluation of P-IP on hydration and barrier function
Effects of P-IP on improvement of skin hydration and TEWL were examined.
|
2% dosage, oil-in-water emulsion, twice a day, 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of skin surface water content and Trans-Epidermal Water Loss (TEWL)
Time Frame: Before application, 1 week, 2 week and 4 weeks after application
|
Subjects were treated with P-IP formulation on one side of the face and with a placebo formulation (without P-IP, oil-in-water emulsion type) on the other side twice daily (morning and evening) for 28 days.
Skin surface water contents and TEWLs were measured at the time frame described above and the results were analyzed as a change from a value of before-application at each measurement.
|
Before application, 1 week, 2 week and 4 weeks after application
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
January 13, 2011
First Submitted That Met QC Criteria
February 25, 2011
First Posted (Estimate)
February 28, 2011
Study Record Updates
Last Update Posted (Estimate)
February 28, 2011
Last Update Submitted That Met QC Criteria
February 25, 2011
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cosmos1
- hydration-1 (Other Identifier: Cosmos Technical Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Skin
-
Ji Hye YoonCOSMAX; Global medical research centerCompletedDry SkinKorea, Republic of
-
Florida State UniversityDermatology Associates of Tallahassee; Quorum InnovationsActive, not recruiting
-
Amorepacific CorporationCompleted
-
Loreal USACompleted
-
GlaxoSmithKlineCompleted
-
NovoBliss Research Pvt LtdOrgenetics, Inc.RecruitingDry Skin | Dry Hair | Hair Falling | Thin Hair | Brittle HairIndia
-
Derming SRLCompleted
-
Anbiome Labs LLCSarajevo School of Science and Technology, Medical School Department; Public...CompletedDry Skin; Eczema | Overall Skin AppearanceBosnia and Herzegovina
Clinical Trials on Pyridoxine tri-isopalmitate
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Federal University of São PauloInstituto Paulista de Estudos e Pesquisa em Oftalmologia; Eye Clinic Day Hospital...Completed
-
Pusan National University HospitalErbe USA IncorporatedRecruitingLung NoduleKorea, Republic of
-
Regional Hospital HolstebroCompleted
-
Institut de Recherche pour le DeveloppementMedical Research Council; Institut Pasteur; Centre Muraz; REVS PLUS Burkina Faso; Young Gambian Mums Fund and other collaboratorsNot yet recruiting
-
Institute for Biomechanics, ETH ZürichCompletedRehabilitation After Ankle InjuriesSwitzerland
-
University Health Network, TorontoCompletedThyroid Neoplasms | Thyroid Cancer | Thyroid NoduleCanada
-
University Hospital, GenevaUnknownCoronary Artery DiseaseSwitzerland
-
Sheba Medical CenterCompleted
-
University Health Network, TorontoCompletedBreast Cancer Invasive Nos | Primary Invasive Breast CancerCanada